Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Samuel Blackman - Co-Founder and Head, R&D Charles York - COO and CFO Conference Call Participants Anupam Rama - JPMorgan Joe Catanzaro - Piper Sandler Andrea Newkirk - Goldman Sachs Soumit Roy - Jones Research Alec Stranahan - Bank of America Ami Fadia - Needham & Company Andres Maldonado - H.C. Wainwri ...

Day One Biopharmaceuticals, Inc. (DAWN) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 290%. A quarter ago, it was expected that this company would post a loss of $0.67 per share when it actually produced a loss of $0.05, delivering a surprise of 92.54%.Over the last four quart ...

f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40431 DAY ONE BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2415215 (State ...

Revenue and Sales Performance - OJEMDA net product revenue reached $20.1 million in Q3 2024, a 145% increase from Q2 2024[2] - Quarterly prescriptions (TRx) for OJEMDA grew to 619 in Q3 2024, representing a 159% increase over Q2 2024[3] - License revenue from the sale of ex-U.S. commercial rights for tovorafenib was $73.7 million in Q3 2024[8] Expenses - Research and development expenses were $33.6 million in Q3 2024, compared to $33.2 million in Q3 2023[9] - Selling, general and administrative expenses increased to $29.0 million in Q3 2024 from $18.3 million in Q3 2023[10] Profitability - Net income for Q3 2024 was $37.0 million, compared to a net loss of $46.2 million in Q3 2023[11] Financial Position - Cash, cash equivalents, and short-term investments totaled $558.4 million as of September 30, 2024[11] Pipeline and Development - Day One plans to advance its pipeline, including the DAY301 program, expected to enter the clinic in the coming months[2] - An exclusive licensing agreement with Ipsen for tovorafenib outside the U.S. included approximately $111 million upfront and potential milestone payments of up to $350 million[6] - The pivotal Phase 3 FIREFLY-2/LOGGIC trial for tovorafenib continues to enroll patients across multiple regions with over 100 sites activated[5]

Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, October 30, 4:30 p.m. Eastern Time BRISBANE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threat ...

ELKHART, Ind., Oct. 30, 2024 /PRNewswire/ -- Hurricane Boats, legendary innovator in versatile deck boat designs, ushers in the next chapter in its storied history with the launch of its latest model for 2025 – the SunDeck 3200. A stunning extension of their current yacht series line-up which includes the 2600 and 2690, the SunDeck 3200 is the latest high point of Hurricane Boats' designs. Hurricane Boats, legendary innovator in versatile deck boat designs, ushers in the next chapter in its storied history ...

Day One Biopharmaceuticals, Inc. (DAWN) closed the last trading session at $15.01, gaining 1.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $36.13 indicates a 140.7% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $6.33. While the lowest estimate of $24 indicates a 59.9% increase from the current price level, the most opt ...

BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Wednesday, October 30, 2024 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2024. Live audio of the webcast will be accessible ...

When volatility strikes the stock market as it sets new highs, investors get nervous. Wild swings in price can often signal a market top. After setting a new record high last month, the S&P 500 has peeled back 5% from that level. A string of upcoming economic indicators coming out this week could determine whether the economy is heading into a recession or if the Federal Reserve will cut interest rates. Stocks are flailing to and fro as investors try to gauge the direction. Yet analysts at Bank of America ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new ...